Literature DB >> 30478765

Real-World Success of Biologic Therapy in IBD: No More Reasons to Be Anti Antibody.

Neil Gordon1, Shaji Sebastian2,3.   

Abstract

Mesh：

Substances：

Year:  2019        PMID： 30478765     DOI： 10.1007/s10620-018-5385-9

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  10 in total

Review 1.  Interpreting Registrational Clinical Trials of Biological Therapies in Adults with Inflammatory Bowel Diseases.

Authors:  Subrata Ghosh; William J Sandborn; Jean-Frederic Colombel; Brian G Feagan; Remo Panaccione; Stephen Hanauer; Stefan Schreiber; Laurent Peyrin-Biroulet; Severine Vermeire; Samantha Eichner; Bidan Huang; Anne M Robinson; Brandee Pappalardo
Journal:  Inflamm Bowel Dis       Date:  2016-11       Impact factor: 5.325

2.  Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population.

Authors:  Christina Ha; Thomas A Ullman; Corey A Siegel; Asher Kornbluth
Journal:  Clin Gastroenterol Hepatol       Date:  2012-02-15       Impact factor: 11.382

3.  Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.

Authors:  Jean-Frédéric Colombel; William J Sandborn; Paul Rutgeerts; Robert Enns; Stephen B Hanauer; Remo Panaccione; Stefan Schreiber; Dan Byczkowski; Ju Li; Jeffrey D Kent; Paul F Pollack
Journal:  Gastroenterology       Date:  2006-11-29       Impact factor: 22.682

4.  Infliximab, azathioprine, or combination therapy for Crohn's disease.

Authors:  Jean Frédéric Colombel; William J Sandborn; Walter Reinisch; Gerassimos J Mantzaris; Asher Kornbluth; Daniel Rachmilewitz; Simon Lichtiger; Geert D'Haens; Robert H Diamond; Delma L Broussard; Kezhen L Tang; C Janneke van der Woude; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2010-04-15       Impact factor: 91.245

5.  Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease.

Authors:  Konstantinos Karmiris; Gilles Paintaud; Maja Noman; Charlotte Magdelaine-Beuzelin; Marc Ferrante; Danielle Degenne; Karolien Claes; Tamara Coopman; Nele Van Schuerbeek; Gert Van Assche; Severine Vermeire; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2009-08-05       Impact factor: 22.682

6.  Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.

Authors:  Jean-Frederic Colombel; Remo Panaccione; Peter Bossuyt; Milan Lukas; Filip Baert; Tomas Vaňásek; Ahmet Danalioglu; Gottfried Novacek; Alessandro Armuzzi; Xavier Hébuterne; Simon Travis; Silvio Danese; Walter Reinisch; William J Sandborn; Paul Rutgeerts; Daniel Hommes; Stefan Schreiber; Ezequiel Neimark; Bidan Huang; Qian Zhou; Paloma Mendez; Joel Petersson; Kori Wallace; Anne M Robinson; Roopal B Thakkar; Geert D'Haens
Journal:  Lancet       Date:  2017-10-31       Impact factor: 79.321

7.  Adalimumab Monotherapy and a Combination with Azathioprine for Crohn's Disease: A Prospective, Randomized Trial.

Authors:  Takayuki Matsumoto; Satoshi Motoya; Kenji Watanabe; Tadakazu Hisamatsu; Hiroshi Nakase; Naoki Yoshimura; Tetsuya Ishida; Shingo Kato; Tomoo Nakagawa; Motohiro Esaki; Masakazu Nagahori; Toshiyuki Matsui; Yuji Naito; Takanori Kanai; Yasuo Suzuki; Masanori Nojima; Mamoru Watanabe; Toshifumi Hibi
Journal:  J Crohns Colitis       Date:  2016-08-26       Impact factor: 9.071

Review 8.  Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.

Authors:  L Peyrin-Biroulet; W Sandborn; B E Sands; W Reinisch; W Bemelman; R V Bryant; G D'Haens; I Dotan; M Dubinsky; B Feagan; G Fiorino; R Gearry; S Krishnareddy; P L Lakatos; E V Loftus; P Marteau; P Munkholm; T B Murdoch; I Ordás; R Panaccione; R H Riddell; J Ruel; D T Rubin; M Samaan; C A Siegel; M S Silverberg; J Stoker; S Schreiber; S Travis; G Van Assche; S Danese; J Panes; G Bouguen; S O'Donnell; B Pariente; S Winer; S Hanauer; J-F Colombel
Journal:  Am J Gastroenterol       Date:  2015-08-25       Impact factor: 10.864

9.  Retention Rate, Persistence and Safety of Adalimumab in Inflammatory Bowel Disease: A Real-Life, 9-Year, Single-Center Experience in Italy.

Authors:  Alessandro Sartini; Eleonora Scaioli; Elisa Liverani; Matteo Bellanova; Luigi Ricciardiello; Franco Bazzoli; Andrea Belluzzi
Journal:  Dig Dis Sci       Date:  2018-10-17       Impact factor: 3.199

Review 10.  Anti-TNF Therapy in Crohn's Disease.

Authors:  Samuel O Adegbola; Kapil Sahnan; Janindra Warusavitarne; Ailsa Hart; Philip Tozer
Journal:  Int J Mol Sci       Date:  2018-07-31       Impact factor: 5.923
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.